Meet Our Talented and Dedicated Team
At Telescope Therapeutics we are revolutionizing preclinical drug development by harnessing the power of patient-derived inducible pluripotent stem cells (iPSCs) and advanced biosensor technologies. Our mission is to transform how diseases are modeled, therapies are discovered, and drug efficacy is predicted—accelerating the journey from the lab to the patient.
Our Team
Our multidisciplinary team of scientists and professionals is dedicated to pushing the boundaries of preclinical research. With expertise in stem cell biology, pharmacology, bioengineering, and computational modeling, we collaborate to develop innovative solutions that address the complexities of human diseases.
As the Chief Scientific Officer of Telescope Therapeutics and a Professor in the Department of Pharmacology and Therapeutics, Terry has a long-standing track record in the identification of molecular mechanisms involved in the function of GPCRs publishing more than 195 papers (h-index 56). His work centers on novel signaling complexes and pathways associated with subcellular localization of GPCRs and G proteins, with a recent focus on using biosensors in iPSC-based models of disease for drug discovery. Fun Fact: he loves to play harmonica and sing “House of the Rising Sun”.
Nadia is a renowned cardiologist, McGill graduate with Stanford fellowship. She has participated in the care of over 1000 patients with heart failure, transplant or ventricular assist devices. As the Associate Physician-in-Chief, she is former Chief of Cardiology and former Medical Director of the Heart Failure and Heart Transplant program at the MUHC. Nadia's research on personalized therapy combined with her leadership in managing medical programs, place her as a valuable asset for Telescope Therapeutics.
As a cardiothoracic surgeon at the Montreal Children's Hospital and The Royal Victoria Hospital in Montreal, Renzo was leading the Heart Failure and Heart Transplant Program of the MUHC. Renzo has a proven track record in securing funding for innovative projects. He is active in clinical and translational research and has brought multiple new technologies to the MUHC. His research interests include new technologies and treatments for the management of heart failure.
Suleen has extensive expertise in stem cell research and organoid development. Her work at Telescope Therapeutics is centered on establishing an iPSC platform to model cardiac and kidney diseases in vitro, while also supporting the company's business development efforts. During her PhD, Suleen has pioneered protocols for generating esophageal and tracheal organoids, contributing to rare disease research. Fun fact: Suleen is also a published author of a children’s book about a rare congenital disease, EA/TEF.
Jana is responsible for the translational science of the drug-discovery pipeline. Her PhD on studying the function of a mitochondrial protein gave her a wide background in cell biology and developing or validating biochemical methods. She started as a Post-Doc in the Hébert lab where she screened GPCR-targeting compounds in iPSC-derived cardiomyocytes. As the CPO at Telescope Therapeutics Jana built the drug screening platform and partially the company by participating in the business development and helping with HR. Outside of work you might find her in a climbing gym or in the kitchen where she is making incredible things from scratch.
As the newest member to join TT, Maleny (she finds her name too long) is doing a Mitacs-Stem Cell Network industry-based internship. Her focus is on exploring the business side of TT as an emerging biotech startup, particularly in de-risking business development strategies and validating market needs. She studied Biotechnology Engineering at Tec de Monterrey, Mexico, and is currently pursuing a Master’s in Biomedical Engineering at the University of Calgary.
As a Scientist at Telescope Therapeutics and Master’s student in the department of Biochemistry at McGill, Ben leverages his background in cancer mechanisms and organoid modeling in establishing iPSC models at the company. His passion for this field of research stems from its fascinating potential to personalize medicine and run “clinical trials in a dish”. An avid reader, Ben can be found buried in an adventure novel, at the gym or biking around Montréal.
Jiajia will contribute to the establishment of the drug screening platform at TT. She holds a degree in Veterinary Medicine from Zhejiang University, China, and is currently pursuing a Master’s in Biotechnology at McGill University. In her internship with the Hébert lab, she is working with biosensors for GPCR related drug screening. Outside of the lab, she is a dedicated guqin (an ancient Chinese string instrument) player and enjoys painting.
Our multidisciplinary team of scientists and professionals is dedicated to pushing the boundaries of preclinical research. With expertise in stem cell biology, pharmacology, bioengineering, and computational modeling, we collaborate to develop innovative solutions that address the complexities of human diseases.
As the Chief Scientific Officer of Telescope Therapeutics and a Professor in the Department of Pharmacology and Therapeutics, Terry has a long-standing track record in the identification of molecular mechanisms involved in the function of GPCRs publishing more than 195 papers (h-index 56). His work centers on novel signaling complexes and pathways associated with subcellular localization of GPCRs and G proteins, with a recent focus on using biosensors in iPSC-based models of disease for drug discovery. Fun Fact: he loves to play harmonica and sing “House of the Rising Sun”.
Nadia is a renowned cardiologist, McGill graduate with Stanford fellowship. She has participated in the care of over 1000 patients with heart failure, transplant or ventricular assist devices. As the Associate Physician-in-Chief, she is former Chief of Cardiology and former Medical Director of the Heart Failure and Heart Transplant program at the MUHC. Nadia's research on personalized therapy combined with her leadership in managing medical programs, place her as a valuable asset for Telescope Therapeutics.
As a cardiothoracic surgeon at the Montreal Children's Hospital and The Royal Victoria Hospital in Montreal, Renzo was leading the Heart Failure and Heart Transplant Program of the MUHC. Renzo has a proven track record in securing funding for innovative projects. He is active in clinical and translational research and has brought multiple new technologies to the MUHC. His research interests include new technologies and treatments for the management of heart failure.
Suleen has extensive expertise in stem cell research and organoid development. Her work at Telescope Therapeutics is centered on establishing an iPSC platform to model cardiac and kidney diseases in vitro, while also supporting the company's business development efforts. During her PhD, Suleen has pioneered protocols for generating esophageal and tracheal organoids, contributing to rare disease research. Fun fact: Suleen is also a published author of a children’s book about a rare congenital disease, EA/TEF.
Jana is responsible for the translational science of the drug-discovery pipeline. Her PhD on studying the function of a mitochondrial protein gave her a wide background in cell biology and developing or validating biochemical methods. She started as a Post-Doc in the Hébert lab where she screened GPCR-targeting compounds in iPSC-derived cardiomyocytes. As the CPO at Telescope Therapeutics Jana built the drug screening platform and partially the company by participating in the business development and helping with HR. Outside of work you might find her in a climbing gym or in the kitchen where she is making incredible things from scratch.
As the newest member to join TT, Maleny (she finds her name too long) is doing a Mitacs-Stem Cell Network industry-based internship. Her focus is on exploring the business side of TT as an emerging biotech startup, particularly in de-risking business development strategies and validating market needs. She studied Biotechnology Engineering at Tec de Monterrey, Mexico, and is currently pursuing a Master’s in Biomedical Engineering at the University of Calgary.
As a Scientist at Telescope Therapeutics and Master’s student in the department of Biochemistry at McGill, Ben leverages his background in cancer mechanisms and organoid modeling in establishing iPSC models at the company. His passion for this field of research stems from its fascinating potential to personalize medicine and run “clinical trials in a dish”. An avid reader, Ben can be found buried in an adventure novel, at the gym or biking around Montréal.
Jiajia will contribute to the establishment of the drug screening platform at TT. She holds a degree in Veterinary Medicine from Zhejiang University, China, and is currently pursuing a Master’s in Biotechnology at McGill University. In her internship with the Hébert lab, she is working with biosensors for GPCR related drug screening. Outside of the lab, she is a dedicated guqin (an ancient Chinese string instrument) player and enjoys painting.
Our multidisciplinary team of scientists and professionals is dedicated to pushing the boundaries of preclinical research. With expertise in stem cell biology, pharmacology, bioengineering, and computational modeling, we collaborate to develop innovative solutions that address the complexities of human diseases.
As the Chief Scientific Officer of Telescope Therapeutics and a Professor in the Department of Pharmacology and Therapeutics, Terry has a long-standing track record in the identification of molecular mechanisms involved in the function of GPCRs publishing more than 195 papers (h-index 56). His work centers on novel signaling complexes and pathways associated with subcellular localization of GPCRs and G proteins, with a recent focus on using biosensors in iPSC-based models of disease for drug discovery. Fun Fact: he loves to play harmonica and sing “House of the Rising Sun”.
Nadia is a renowned cardiologist, McGill graduate with Stanford fellowship. She has participated in the care of over 1000 patients with heart failure, transplant or ventricular assist devices. As the Associate Physician-in-Chief, she is former Chief of Cardiology and former Medical Director of the Heart Failure and Heart Transplant program at the MUHC. Nadia's research on personalized therapy combined with her leadership in managing medical programs, place her as a valuable asset for Telescope Therapeutics.
As a cardiothoracic surgeon at the Montreal Children's Hospital and The Royal Victoria Hospital in Montreal, Renzo was leading the Heart Failure and Heart Transplant Program of the MUHC. Renzo has a proven track record in securing funding for innovative projects. He is active in clinical and translational research and has brought multiple new technologies to the MUHC. His research interests include new technologies and treatments for the management of heart failure.
Suleen has extensive expertise in stem cell research and organoid development. Her work at Telescope Therapeutics is centered on establishing an iPSC platform to model cardiac and kidney diseases in vitro, while also supporting the company's business development efforts. During her PhD, Suleen has pioneered protocols for generating esophageal and tracheal organoids, contributing to rare disease research. Fun fact: Suleen is also a published author of a children’s book about a rare congenital disease, EA/TEF.
Jana is responsible for the translational science of the drug-discovery pipeline. Her PhD on studying the function of a mitochondrial protein gave her a wide background in cell biology and developing or validating biochemical methods. She started as a Post-Doc in the Hébert lab where she screened GPCR-targeting compounds in iPSC-derived cardiomyocytes. As the CPO at Telescope Therapeutics Jana built the drug screening platform and partially the company by participating in the business development and helping with HR. Outside of work you might find her in a climbing gym or in the kitchen where she is making incredible things from scratch.
As the newest member to join TT, Maleny (she finds her name too long) is doing a Mitacs-Stem Cell Network industry-based internship. Her focus is on exploring the business side of TT as an emerging biotech startup, particularly in de-risking business development strategies and validating market needs. She studied Biotechnology Engineering at Tec de Monterrey, Mexico, and is currently pursuing a Master’s in Biomedical Engineering at the University of Calgary.
As a Scientist at Telescope Therapeutics and Master’s student in the department of Biochemistry at McGill, Ben leverages his background in cancer mechanisms and organoid modeling in establishing iPSC models at the company. His passion for this field of research stems from its fascinating potential to personalize medicine and run “clinical trials in a dish”. An avid reader, Ben can be found buried in an adventure novel, at the gym or biking around Montréal.
Jiajia will contribute to the establishment of the drug screening platform at TT. She holds a degree in Veterinary Medicine from Zhejiang University, China, and is currently pursuing a Master’s in Biotechnology at McGill University. In her internship with the Hébert lab, she is working with biosensors for GPCR related drug screening. Outside of the lab, she is a dedicated guqin (an ancient Chinese string instrument) player and enjoys painting.